Arimoclomol CAS No.:289893-25-0

Arimoclomol CAS No.:289893-25-0 is a highly innovative drug that is gaining prominence in the pharmaceutical industry for its multi-faceted health benefits. The compound can be used to treat a wide range of medical conditions such as neurodegenerative diseases to lysosomal storage disorders.

Arimoclomol is a small molecular weight compound that is well-tolerated and easy to administer. It is orally bioavailable, and it has demonstrated promising neuroprotective effects in various preclinical models. The compound’s mechanism of action involves the stimulation of the lysosome and proteasome systems, a cellular cleanup pathway, which helps to remove misfolded or denatured proteins as well as prevent their accumulation in the cell.

Arimoclomol has been extensively studied in various animal models of neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Huntington's disease and Spinal muscular atrophy (SMA), and it has shown remarkable efficacy in preventing motor neuron cell death, restoring nerve-muscle connections, and improving muscle strength, among others.

In addition to its neuroprotective properties, Arimoclomol has also been investigated for its potential therapeutic uses in lysosomal storage diseases. These are a group of rare genetic disorders that affect various organs and tissues in the body, such as the brain, liver, spleen, bones, and cartilage. By promoting the lysosomal function, Arimoclomol can help to reduce the buildup of waste materials in the cell, which often causes progressive damage and dysfunction of the affected tissues.

One of the key advantages of Arimoclomol over other pharmaceuticals is its favorable safety profile. The drug has been well-tolerated in both preclinical and clinical studies, with no significant adverse effects reported. Also, Arimoclomol holds great promise as a disease-modifying therapy for ALS and other neurodegenerative conditions. This means that the drug is capable of slowing down or halting the progression of the disease, rather than just alleviating its symptoms as many current treatments do.

Overall, Arimoclomol is a highly innovative and promising pharmaceutical compound that holds great potential for the treatment of various medical conditions. Its unique mechanism of action, favorable safety profile, and efficacy in preclinical and clinical trials make it a highly attractive product for wholesalers and merchants operating in the healthcare and pharmaceutical sectors.

As a manufacturer of Arimoclomol, we take pride in producing high-quality products that meet the highest standards of safety and efficacy. Our manufacturing process is fully compliant with international regulatory standards, and we use advanced technologies and equipment to ensure the quality and purity of our products.

In conclusion, Arimoclomol is a highly innovative and promising compound that has the potential to revolutionize the treatment of neurodegenerative diseases and lysosomal storage disorders. Its unique mechanism of action, favorable safety profile, and disease-modifying properties make it an attractive product for wholesalers and merchants looking to expand their product portfolios in the healthcare and pharmaceutical sectors. We are committed to providing high-quality products to our clients and ensuring that Arimoclomol is accessible to those who need it the most.

Chemical Structure : Arimoclomol

CAS No.: 289893-25-0

 

Arimoclomol(BRX-220;BRX 220;BRX220)

Catalog No.: URK-V2228 Only Used For Lab.

Arimoclomol (BRX-220) is a nontoxic heat shock protein (HSP) coinducer and potentiator of the heat shock response

Biological Activity

Arimoclomol (BRX-220) is a nontoxic heat shock protein (HSP) coinducer and potentiator of the heat shock response.
Arimoclomol (BRX-220) significantly increases pancreatic levels of HSP60 and HSP72 in vivo, significantly delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS.

Physicochemical Properties

References

1. Kieran D, et al. Nat Med. 2004 Apr;10(4):402-5.

2. Parfitt DA, et al. Cell Death Dis. 2014 May 22;5:e1236.

3. Rakonczay Z Jr, et al. Free Radic Biol Med. 2002 Jun 15;32(12):1283-92.

4. Kalmar B, et al. J Neurochem. 2008 Oct;107(2):339-50.

URK-V2228_COA

URK-V2228_SDS

URK-V2228_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• Our team is dedicated to meeting the highest standards of quality.
• After careful research and assiduous research, we are able to provide you reliable and efficient Arimoclomol CAS No.:289893-25-0.
• We pride ourselves on providing exceptional customer service.
• We hope that every employee should regard the overall interests of the group as the highest interest and cooperate with each other to achieve mutual benefit and win-win situation.
• We are constantly innovating and developing new products to meet evolving customer needs.
• The company will continue to adhere to the business philosophy of "honesty and trust", continuously improve the core competitiveness of the company, promote the transformation and upgrading of the industrial structure, and accelerate the conversion of new and old kinetic energy to achieve greater economic and social benefits.
• We offer personalized service to meet the unique needs of each customer.
• The company adheres to the business philosophy of market-oriented, innovation-oriented, and quality-oriented, to provide customers with competitive products.
• Our products are backed by a comprehensive warranty and money-back guarantee.
• Our company produces products with exquisite workmanship, novel style, excellent inner material and beautiful appearance. Our Arimoclomol CAS No.:289893-25-0 are sold all over the world and are highly praised by foreign businessmen.

Hot Tags: arimoclomol cas no.:289893-25-0, China arimoclomol cas no.:289893-25-0, epigenetic library for epigenetic regulation of cell activation, epigenetic library for epigenetic analysis of epigenetic diversity, agonists for cardiovascular research, epigenetic library for epigenetic analysis of histone modification, agonists for adjuvant activity, epigenetic library for epigenetic analysis of epigenetic syndrome